BioTuesdays

Category - News

Profound Medical Logo

Profound Medical sells first TULSA-PRO device

Profound Medical (TSX-V:PRN) has made the first sale of its TULSA-PRO device to ResoFus Alomar in Barcelona, Spain. Profound’s novel technology combines real-time magnetic resonance imaging with transurethral...

Strongbridge Biopharma Logo

HCW starts Strongbridge Biopharma at buy

H.C. Wainwright has initiated coverage of Strongbridge Biopharma (NASDAQ:SBBP) with a “buy” rating and $15 price target. The stock closed at $5.23 on Tuesday. “Within the span of two years, Strongbridge has made...

novadaq

Novadaq posts 52% jump in Q1 revenue

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported first quarter revenue of $17.7-million, up 52%, from $11.7-million a year ago. Total direct sales in the quarter rose by $6.1-million, or 71%, and total...

Trovagene Logo

Leerink downgrades Trovagene to market perform

Leerink Partners has downgraded Trovagene (NASDAQ:TROV) to “market perform” from “outperform” and lowered its price target to $4.50 from $8, following the recent removal/departure of key senior management. The stock...

Celator Pharmaceuticals

Stifel starts Celator Pharma at buy

Stifel has initiated coverage of Celator Pharmaceuticals (NASDAQ:CPXX) with a “buy” rating and a 12-month target price of $23. The stock closed at $15.52 on Thursday. Analyst Stephen Willey writes that recently...

Windtree Therapeutics

HCW starts Windtree Therapeutics at buy

H.C. Wainwright has launched coverage of Windtree Therapeutics (NASDAQ:WINT) with a “buy” rating and $8 price target, ahead of study readouts on tap for the next 12 months. The stock closed at $3.03 on Thursday. “We...

Cerus

BTIG ups Cerus price target to $10

BTIG Research has raised its price target for Cerus (NASDAQ:CERS) to $10 from $8, saying the progress made by the company has “exceeded even our bullish expectations.” The stock closed at $6.65 on Thursday. Cerus is a...